-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SurVaxM in Pediatric Diffuse Intrinsic Pontine Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SurVaxM in Pediatric Diffuse Intrinsic Pontine Glioma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.SurVaxM in Pediatric Diffuse Intrinsic Pontine GliomaDrug Details:SurVaxM is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Adagloxad Simolenin in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Adagloxad Simolenin in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.Adagloxad Simolenin in Triple-Negative Breast Cancer (TNBC) Drug Details:Adagloxad simolenin...
-
Product Insights
Net Present Value Model: Yselty
Overview Evaluating the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the market currently and in the future, knowledge of cash inflows and outflows and the potential success rates for each stage of drug development. GlobalData has done all of this work for you, leveraging its gold standard Drugs Intelligence database to create high-value NPV models for purchase on a drug-by-drug basis. Drug Operating Profit Model Yselty Drug Details Linzagolix (Yselty) is...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Vaccine to Target CA19-9 for Metastatic Breast Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry Vaccine to Target CA19-9 for Metastatic Breast Cancer Drug Details Vaccine is under development...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Vaccine to Target IFN-Alpha for Metabolic Disorders, Immunology, Infectious Diseases and Musculoskeletal Disorders
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry Vaccine to Target IFN-Alpha for Metabolic Disorders, Immunology, Infectious Diseases and Musculoskeletal Disorders Drug...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – SurVaxM
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry SurVaxM Drug Details SurVaxM is under development for the treatment of glioblastoma, recurrent gioblastoma,...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – adagloxad simolenin
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry adagloxad simolenin Drug Details Adagloxad simolenin (OBI-222) is under development for the treatment of...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – linzagolix choline
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data to allow you to track and predict specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using a combination of machine learning and proprietary models. Likelihood of Approval (LoA) - Industry linzagolix choline Drug Details Linzagolix (Yselty) is a small-molecule, non-peptide, orally active gonadotropin-releasing hormone...